A role of 1,25(OH)2D3 supplementation in rats with nonalcoholic steatohepatitis induced by choline-deficient diet

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 6, 2015, Pages 556-561

  Han, H ^a   Cui, M ^b   You, X ^a   Chen, M ^a   Piao, X ^a   Jin, G ^b  

^a YANBIAN UNIVERSITY   (China)

^b YANBIAN UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

1,25(OH)2D3; 25 (OH)D3; Choline; Nonalcoholic steatohepatitis; Vitamin D receptor

Indexed keywords

CALCITRIOL; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; VITAMIN D RECEPTOR; ANTIOXIDANT; LIPID; TISSUE INHIBITOR OF METALLOPROTEINASE-1 PROTEIN, RAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CELL ACTIVATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPID PEROXIDATION; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; RAT; STELLATE CELL; TUNEL ASSAY; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ANIMAL; APOPTOSIS; BLOOD; COMPLICATION; DIET; DIETARY SUPPLEMENT; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; RISK FACTOR; TIME FACTOR; TOXICITY; VITAMIN DEFICIENCY; WISTAR RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CALCITRIOL; CHOLINE DEFICIENCY; DIET; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATIC STELLATE CELLS; LIPIDS; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS, WISTAR; RISK FACTORS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84930179342     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2015.02.011     Document Type: Article

References (28)

1. Zeisel S.H., Blusztajn J.K. Choline and human nutrition. Annu Rev Nutr 1994, 14:269-296.
2. Pacifico L., Anania C., Martino F., Poggiogalle E., Chiarelli F., Arca M., et al. Management of metabolic syndrome in children and adolescents. Nutr Metab Cardiovasc Dis 2011, 21(6):455-466.
3. Kawaratani H., Tsujimoto T., Kitazawa T., Kitade M., Yoshiji H., Uemura M., et al. Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J Gastroenterol 2008, 14(43):6655-6661.
4. Targher G., Bertolini L., Scala L., Cigolini M., Zenari L., Falezza G., et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007, 17(7):517-524.
5. Nakano T., Cheng Y.F., Lai C.Y., Hsu L.W., Chang Y.C., Deng J.Y., et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 2011, 55(2):415-425.
6. Han H.M., Chen M.H., Piao D.M., Cui M.H., Piao X.X. Effect of supplement l,25-Dihydroxyvitamin D3 with non-alcoholic steatohepatitis (NASH) in rat as well as related mechanisms (in chinese) CJPT 2014, [Epub ahead of print].
7. Reeves P.G., Rossow K.L., Lindlauf J. Development and testing of the AIN-93 purified diets for rodents: results on growth, kidney calcification and bone mineralization in rats and mice. J Nutr 1993, 123(11):1923-1931.
8. Schumann G., Bonora R., Ceriotti F., Férard G., Ferrero C.A., Franck P.F., et al. International federation of clinical chemistry and laboratory medicine. IFCC primary reference procedures for measurement of catalytic activity concentrations of enzymes at 37°C. international federation of clinical chemistry and laboratory medicine. part 4. Reference procedure for the measurement of catalytic concentrations of alanine aminotransferase. Clin Chem Lab Med 2003, 40(7):718-724.
9. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
10. Kwok R.M., Torres D.M., Harrison S.A. Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association?. Hepatology 2013, 58(3):1166-1174.
11. Haussler M.R., Jurutka P.W., Mizwicki M., Norman A.W. Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)2 vitamin D3: genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab 2011, 25(4):543-559.
12. Martins M.A., Martins P.M., Faria Neto H.C., Bozza P.T., Dias P.M., Cordeiro R.S., et al. Intravenous injections of PAF-acether induce platelet aggregation in rats. Eur J Pharmacol 1988, 149(1-2):89-96.
13. Canbay A., Bechmann L., Gerken G. Lipid metabolism in the liver. Z Gastroenterol 2007, 45(1):35-41.
14. Yamaguchi K., Yang L., Mccall S., Huang J., Yu X.X., Pandey S.K., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with non-alcoholic steatohepatitis. Hepatology 2007, 45(6):1366-1374.
15. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2008, 23(3):501-502.
16. Sharifi N., Amani R., Hajiani E., Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine 2014, 47(1):70-80.
17. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125(2):437-443.
18. Malhi H., Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):360-369.
19. Wree A., Kahraman A., Gerken G., Canbay A. Obes affects liver -the link between adipocytes hepatocytes. Digestion 2011, 83(1-2):124-133.
20. Zhang A., Wang Y., Xie H., Zheng S. Calcitriol inhibits hepatocyte apoptosis in rat allograft by regulating apoptosis-associated genes. Int Immunopharmacol 2007, 7(8):1122-1128.
21. Maliken B.D., Nelson J.E., Klintworth H.M., Beauchamp M., Yeh M.M., Kowdley K.V. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 2013, 57(5):1806-1813.
22. Manco M., Ciampalini P., Nobili V. Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease. Hepatology 2010, 51(6):2229.
23. Barchetta I., Angelico F., Del Ben M., Baroni M.G., Pozzilli P., Morini S., et al. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011, 9:85.
24. Kasapoglu B., Turkay C., Yalcin K.S., Carlioglu A., Sozen M., Koktener A. Low vitamin D levels are associated with increased risk for fatty liver disease among non-obese adults. Clin Med 2013, 13(6):576-579.
25. Eliades M., Spyrou E., Agrawal N., Lazo M., Brancati F.L., Potter J.J., et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013, 38(3):246-254.
26. Eraslan S., Kizilgul M., Uzunlulu M., Colak Y., Ozturk O., Tuncer I. Frequency of metabolic syndrome and 25-hydroxyvitamin D3 levels in patients with non-alcoholic fatty liver disease. Minerva Med 2013, 104(4):447-453.
27. Adams J.S., Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010, 95(2):471-478.
28. Korgavkar K., Xiong M., Weinstock M.A. Review: higher vitamin D status and supplementation may be associated with risks. Eur J Dermatol 2014, 24(4):428-434.